Disseminated on behalf of CERo Therapeutics Holdings, Inc.
Cancer treatments have come a long way over the years, but there is a newer treatment that is providing even stage four cancer patients with a new lease on life.
The first CAR T-cell therapy was only approved in 2017, but its already having a significant impact in the cancer treatment market. The latest success story comes from Sandra Hajlo, who just became the first person in Manitoba to be declared cancer-free following CAR T-cell therapy.1
Initially diagnosed with stage four B-cell lymphoma in 2015, Hajlo underwent successful chemotherapy. However, eight years later, her cancer returned, leading to another battle with the disease. After a misdiagnosis of scoliosis, a CT scan revealed her cancer had come back.
Her oncologist recommended CAR T-cell therapy, a new treatment where T-cells are modified to target cancer cells, making her the first recipient of this therapy at CancerCare Manitoba.
Dr. David Szwajcer, Manitoba Blood & Marrow Transplant Director at CancerCare Manitoba, explained that the CAR T-cells are collected, sent to a U.S. facility for modification, and then reintroduced to the patient. Hajlo described the procedure as quick and straightforward, taking only 20 minutes.
After undergoing CAR T-cell therapy in December 2023, Hajlo learned in April 2024 that the treatment was successful, and she is cancer-free once again, expressing her gratitude for the second chance at life.
CAR T-cell therapy does not guarantee survival, with about half of the patients not responding,but it has shown promising results in many cases.
CERo Therapeutics Holdings (NASDAQ:CERO) is an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics. CERo Therapeutics is unrelated to CancerCare Manitoba and had no role in the CAR T-cell therapy described above. Nevertheless, CERo Therapeutics believes that the success of the CAR T-cell therapy in Manitoba may provide an indication of the potential for its proprietary CER-T (chimeric engulfment receptor) cell therapy.
CAR-T cell treatment has a steep price tag and some potential serious side effects including secondary cancer developing2 as well as cytokine release syndrome (CRS),3 which causes your immune system to go into overdrive and is potentially life threatening. CER-T cell therapy may provide a more cost-effective alternative with fewer side effects.
CERo Advances Innovative Cancer Immunotherapy
CERo Therapeutics (NASDAQ:CERO)developed CER-T cells to enhance efficiency and reduce side effects compared to traditional therapies by leveraging the body's natural tumor-fighting mechanisms. CER-T cells achieve this through direct tumor killing and by amplifying the body's anti-tumor immune response, and additionally by presenting cancer cell fragments to other immune cells, drawing these cells to attack the tumor.
Peer-reviewed data shows that CER-T cells have at least eight anticancer functions, offering potent, durable, and low-toxicity therapeutic benefits, with the capability to completely eliminate tumors. The company has validated these findings in 10 animal experiments, including a study on Acute Myeloid Leukemia (AML) published in March 2024.
CERoTherapeutics believes CER-T cells offer greater therapeutic potential than currently approved chimeric antigen receptor (CAR-T) cell therapy, potentially targeting both hematological malignancies and solid tumors. The company plans to begin clinical trials for its lead product candidate, CER-1236, in 2024 for treating hematological malignancies.
CERo has been diligently completing pre-clinical studies and documentation necessary to initiate clinical trials after gaining approval from the FDA for its Investigational New Drug (IND) Application.
CERo Therapeutics Holdings, Inc., (NASDAQ:CERO) has successfully completed toxicity studies for CER-1236, a critical step before applying to the FDA for approval to begin human trials. With these studies showing that CER-1236 can be safely administered, the company is now focusing on ensuring safe manufacturing and finalizing its FDA application. Upon FDA acceptance, the company would be able to commence Phase 1 clinical trials, marking the start of the journey toward US approval and addressing unmet medical needs.
CERo plans to update shareholders on their progress, including presentations at investor conferences, potential growth of their intellectual property portfolio, and advancements in other programs beyond AML.
1) The author of the Article, or members of the authors immediate household or family, do not own any securities of the companies outlined in this Article. The author determined which companies would be included in this article based on research and understanding of the sector.
2) The Article was issued on behalf of and sponsored by, CERo Therapeutics Holdings, Inc. Market Jar Media Inc. was paid $1,500 USD for the production and publishing of this article by CERo Therapeutics Holdings, Inc.s Digital Marketing Agency of Record (Native Ads Inc.). Additional details relating to Market Jar Media Inc.s engagement by CERo Therapeutics Holdings, Inc.s Digital Marketing Agency of Record (Native Ads Inc.) are set out in https://pressreach.com/disclaimer-cero.
3) Statements and opinions expressed are the opinions of the author and not Market Jar Media Inc., its directors or officers. The author is wholly responsible for the validity of the statements. The author was not paid by Market Jar Media Inc. for this Article. Market Jar Media Inc. was not paid by the author to publish or syndicate this Article. Market Jar has not independently verified or otherwise investigated all such information. None of Market Jar or any of their respective affiliates, guarantee the accuracy or completeness of any such information. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security. Market Jar Media Inc. requires contributing authors to disclose any shareholdings in, or economic relationships with, companies that they write about. Market Jar Media Inc. relies upon the authors to accurately provide this information and Market Jar Media Inc. has no means of verifying its accuracy.
4) The Article does not constitute investment advice. All investments carry risk and each reader is encouraged to consult with his or her individual financial professional. Any action a reader takes as a result of the information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Market Jar Media Inc.'s terms of use and full legal disclaimer as set forth here. This Article is not a solicitation for investment. Market Jar Media Inc. does not render general or specific investment advice and the information on PressReach.com should not be considered a recommendation to buy or sell any security. Market Jar Media Inc. does not endorse or recommend the business, products, services or securities of any company mentioned on PressReach.com.
5) Market Jar Media Inc. and its respective directors, officers and employees hold no shares for any company mentioned in the Article.
6) This communication contains statements that are forward-looking and as such are not historical facts. This includes, without limitation, statements regarding the financial position, business strategy and the plans and objectives of management for future operations of CERo. These statements constitute projections, forecasts and forward-looking statements, and are not guarantees of performance. Such statements can be identified by the fact that they do not relate strictly to historical or current facts. When used in this communication, words such as anticipate, believe, continue, could, estimate, expect, intend, may, might, plan, possible, potential, predict, project, should, strive, would and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. When CERo discusses its strategies or plans, it is making projections, forecasts or forward-looking statements. Such statements are based on the beliefs of, as well as assumptions made by and information currently available to, CERos management. Actual results could differ from those implied by the forward-looking statements in this communication. Certain risks that could cause actual results to differ are set forth in CERos filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K, filed on April 2, 2024, and the documents incorporated by reference therein. The risks described in CERos filings with the Securities and Exchange Commission are not exhaustive. New risk factors emerge from time to time and it is not possible to predict all such risk factors, nor can CERo assess the impact of all such risk factors on its business, or the extent to which any factor or combination of factors may cause actual results to differ materially from those contained in any forward-looking statements. Forward-looking statements are not guarantees of performance. You should not put undue reliance on these statements, which speak only as of the date hereof. All forward-looking statements made by CERo or persons acting on its behalf are expressly qualified in their entirety by the foregoing cautionary statements. CERo undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
7) Any graphs, tables or other information demonstrating the historical performance or current or historical attributes of CERo Therapeutics Holdings, Inc. or any other entity contained in this document are intended only to illustrate historical performance or current or historical attributes of CERo Therapeutics Holdings, Inc. or such entities and are not necessarily indicative of future performance of CERo Therapeutics Holdings, Inc. or such entities.
8) Investing is risky. The information provided in this article should not be considered as a substitute for professional financial consultation. Users should be aware that investing in any form carries inherent risks, and as such, there is a possibility of losing some or all of their investment. The value of investments can fluctuate significantly within a short period, and investors must understand that past performance is not indicative of future results. Additionally, users should exercise caution as transactions involving investments may be irreversible, even in cases of fraud or accidental actions. It is crucial to acknowledge that rapidly evolving laws and technical issues can have adverse effects on the usability, transferability, exchangeability, and value of investments. Furthermore, users must be cognizant of potential security risks associated with their investment activities. Individuals are strongly encouraged to conduct thorough research, seek professional advice, and carefully evaluate their risk tolerance before engaging in any investment endeavors. Market Jar Media Inc. is neither an investment adviser nor a broker-dealer. The information presented on the website is provided for informative purposes only and is not to be treated as a recommendation to make any specific investment. No such information on PressReach.com constitutes advice or a recommendation.
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Dubai, UAE, June 18, 2026-GivTrade today reaffirmed its commitment to transparency, regulatory compliance, and client protection as it marks seven years of growth and service to traders across international markets.
Founded in 2019, GivTrade has grown into an international financial services group serving more than 100,000 traders worldwide through its regulated operations and partner network. GivTrade forms part of Fawaz Investment Holding, a Qatar-based investment group supporting the continued growth and development of its international operations.
Givtrade At A Glance
• Established in 2019
• More than 100,000 traders served globally
• UAE CMA Category 5 licensed entity
• FSC Mauritius regulated trading operations
• Headquarters in Qatar through Fawaz Investment Holding (QFC)
• Strategic partnerships with TradingView and LaLiga
• Best Market Execution Technology Award recipient (Jeddah Fintech Week 2025)
• Expanding operations across key international markets
Regulatory Status
GivTrade operates through licensed entities in multiple jurisdictions.
United Arab Emirates
GivTrade Financial Services L.L.C S.O.C holds UAE CMA Category 5 Licence No. 20200000367 issued by the UAE Securities and Commodities Authority (SCA).
Mauritius
Trading services are provided through GivTrade’s regulated entity licensed by the Financial Services Commission (FSC) of Mauritius under Licence No. GB22201329 – Investment Dealer (Full Service Dealer, Excluding Underwriting).
Both licences are active and publicly verifiable through their respective regulators.
Corporate Structure
GivTrade is part of Fawaz Investment Holding, a Qatar-based holding company established within the Qatar Financial Centre (QFC). Fawaz Investment Holding serves as the Group’s holding and operational headquarters, overseeing the strategic development and growth of its affiliated businesses and investments. The holding company does not provide regulated trading services or investment dealing activities to retail clients.
Client-facing regulated activities are conducted exclusively through the Group’s appropriately licensed entities in their respective jurisdictions.
Global Partnerships And Market Presence
GivTrade has established strategic partnerships and marketing collaborations with internationally recognised organisations and platforms, including LaLiga and TradingView.
Industry Recognition
At Jeddah Fintech Week 2025, held in November 2025, GivTrade was honoured with the BestMarket Execution Technology Award, recognising the company’s investment in trading
infrastructure, execution quality, and technology-driven solutions for traders.
Guidance For Traders
GivTrade encourages all traders to verify licences directly through regulator websites, review legal disclosures carefully, and rely on official regulatory records when evaluating financial service providers.
Future Growth And Expansion
Looking ahead, GivTrade continues to invest in its global regulatory framework. In addition to its existing licences and operations, the Group is evaluating further regulatory opportunities, including a future licence application with the Cyprus Securities and Exchange Commission (CySEC), subject to all regulatory approvals and applicable legal requirements.
Statement From The CEO
“The UAE remains one of the most important markets in our long-term growth strategy. As we continue to expand our presence in the region, we are investing in a new larger office in Dubai, growing our team, and strengthening the infrastructure required to support our future ambitions. Together with our regulated international operations, these investments reflect our confidence in the future of GivTrade and our commitment to serving traders with transparency, professionalism, and trust.”
— Hassan Fawaz, Chief Executive Officer
About Givtrade
Founded in 2019, GivTrade is an international financial services group serving more than 100,000 traders worldwide through its regulated operations and partner network. The Group maintains its headquarters in Qatar through Fawaz Investment Holding within the Qatar Financial Centre (QFC) and operates regulated entities in multiple jurisdictions.
This statement is issued for informational purposes only and does not constitute investment advice, an offer, or a solicitation to provide financial services in any jurisdiction where such activity would be restricted or prohibited.
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
New UV-Resistant, Zero-Maintenance Plants Deliver Year-Round Greenery for Homes, Offices, and Outdoor Spaces
CHARLOTTE, NC, United States, 18th Jun 2026 – Vitalismo, a brand specializing in high-quality lifelike artificial plants, has officially expanded its Amazon product lineup with two new decorative tree collections: artificial cedar topiary and artificial olive tree. Designed for both residential and commercial environments, the new additions reflect the growing demand for low-maintenance greenery solutions that combine aesthetics, convenience, and long-term durability.
As consumer interest in nature-inspired interiors continues to rise, artificial plants are becoming an increasingly popular choice for homes, offices, hospitality venues, and retail spaces. Unlike live plants, artificial greenery requires no watering, pruning, fertilizing, or specialized lighting conditions, while maintaining a consistent appearance throughout the year. Advances in simulation craftsmanship and weather-resistant materials have further accelerated adoption of large decorative artificial trees, including olive and cedar varieties, across a wide range of indoor and outdoor settings.
“More consumers today are seeking home décor solutions that balance beauty with convenience,” said a spokesperson for Vitalismo. “Through realistic, low-maintenance artificial plants, we aim to help people create welcoming green spaces that remain vibrant year-round while reducing the effort typically associated with plant care.”
Vitalismo was founded with a simple mission: to help consumers create vibrant, evergreen spaces without the time and resources traditionally required for plant care.
Artificial Cedar and Olive Tree Collections Built Around Evergreen Beauty
Vitalismo’s latest Amazon launches address this trend directly, offering two distinct tree styles that combine detailed craftsmanship with long-term durability and no upkeep requirements.
The Vitalismo Artificial Topiary Cedar Trees are available in five size options, ranging from 2 feet to 6 feet tall. The artificial topiary cedar tree is constructed from high-quality PE material and plastic, with branches and leaves engineered using simulation technology to reproduce the natural layered growth pattern of a cedar tree. The leaves feature clearly defined textures, along with newly designed buds that enhance the sense of organic growth.
A key functional feature is the flexibility of the branches: each unit allows users to bend and reshape the foliage to suit the dimensions and layout of the intended space. This makes the cedar topiary adaptable to narrow entryways, covered patios, balconies, and front porch placements equally well. The trees are odorless, weather-tolerant, and carry a UV-resistant treatment that prevents color fading from prolonged sun exposure, making them suitable for semi-exposed outdoor use as well as indoor display.
Most recently, Vitalismo introduced the Artificial Indoor Olive Trees, which are available in four size options, spanning 5 feet to 8 feet in height. Depending on the size selected, individual units feature between 641 and 1530 meticulously crafted leaves with clear textures, and include decorative artificial olive fruits.
Each unit ships pre-assembled in a heavy-duty pot constructed from durable plastic and concrete for superior stability, and includes a white round planter. The collection has received multiple industry recognitions, including the MUSE Design Awards, American Good Design Award, and Gold Award distinctions, highlighting its realistic appearance, craftsmanship, and decorative versatility.
Looking Ahead
Looking ahead, Vitalismo remains committed to innovation and sustainability, focusing on creating realistic, high-quality artificial plants that bring vibrant greenery to homes, offices, and commercial spaces year-round. The brand plans to continue developing increasingly lifelike and premium products to provide consumers with the experience of a flourishing natural environment without the challenges of traditional plant care.
At the same time, Vitalismo aims to explore more environmentally friendly and durable materials to extend product longevity and reduce resource waste associated with frequent replacements. The company also intends to expand its artificial plant collections to cater to a wider range of decorative needs across different spaces.
Both the Vitalismo Artificial Topiary Cedar Trees and the Artificial Indoor Olive Trees are currently available on Amazon, with multiple size options listed on each product page.
Vitalismo is a brand specializing in high-quality, lifelike artificial plants, dedicated to providing maintenance-free, evergreen decorative solutions for homes and offices. All Vitalismo products feature UV-resistant and fade-resistant finishes, offering a realistic appearance across every product line. The brand’s plants are non-toxic and safe for households with pets and children, making them a practical choice for a wide range of customers.
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
CJ William, a Surfside, Florida luxury watch and Hermes dealer, today released its 2026 Luxury Watch Resale Report. The annual analysis combines public secondary-market indices with dealer transaction activity, finding that Patek Philippe led major brands in 2025 and that select Cartier references quietly outperformed the broader market.
SURFSIDE, Fla. – CJ William, a South Florida luxury watch and Hermes dealer, today released its 2026 Luxury Watch Resale Report, an annual analysis of which timepieces held, gained, or lost value across the secondary market over the past year.
The headline finding: luxury watch resale value turned a corner in 2025. After roughly two years of decline, prices stabilized and the strongest references posted real gains. Patek Philippe led all major brands at about 7.7 percent for the year, driven by the Aquanaut and Nautilus, while Rolex stabilized and Audemars Piguet returned to growth. The report also flags a less obvious trend: select Cartier references outperformed the broader market even as headline hype models cooled.
“Everyone watches the Daytona and the Nautilus, and they should, because top-tier Patek, Rolex, Audemars Piguet and Richard Mille continue to hold and in many cases grow their value,” said Eitan Cohen, founder of CJ William. “But the buyers walking into our Surfside showroom in 2026 are asking smarter questions about value, and brands like Cartier are rewarding them.”
“The white-dial Daytona Panda is the single most-requested watch on our desk right now,” Cohen added. “Steel sports Rolex, the Nautilus and the Aquanaut move fast in South Florida, and Cartier prices have quietly climbed even as demand held steady.”
Key findings from the 2026 report include the top 10 references by value retention over the past year, the brands that recovered fastest after the market correction, where value is hiding in 2026, and a South Florida market cut showing which models move fastest in Miami, Surfside and Bal Harbour.
CJ William compiled the report from leading public secondary-market indices combined with its own buying and selling activity, giving a dealer-side view of real demand rather than listing prices alone.
CJ William buys and sells Rolex, Patek Philippe, Audemars Piguet, Richard Mille, Cartier and other luxury watches, with in-house New York authentication, an 18-month warranty and fully insured FedEx overnight shipping. The firm makes same-day offers and welcomes in-person appointments at its Surfside showroom.
About CJ William
CJ William is a luxury watch, Hermes and antique silver dealer at 9573 Harding Avenue, Surfside, FL 33154. The showroom buys, sells and sources luxury timepieces and offers corporate gifting nationwide. Invoicing entity: David and Sons Watches LLC.
Media Contact CJ William Email: e@cjwilliam.com Phone: (347) 510-0668 Website: cjwilliam.com
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
